Figure 4.
Impact of allogeneic HSCT after mogamulizumab-containing treatment. (A) OS of patients receiving or not receiving allogeneic HSCT. (B) OS of patients who received allogeneic HSCT ≥60 days or <60 days after the last mogamulizumab infusion.
Impact of allogeneic HSCT after mogamulizumab-containing treatment. (A) OS of patients receiving or not receiving allogeneic HSCT. (B) OS of patients who received allogeneic HSCT ≥60 days or <60 days after the last mogamulizumab infusion.